RxDoctor Payments Data

Jacques Winter, MD

Neurology · Huntington, NYNPI 1750469052

Payments from drug & device makers

$1,110in general payments, 2019–2025

Across 21 payments — averaging $52.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$578
  • UCB, Inc.$150
  • Kyowa Kirin, Inc.$125
  • E.r. Squibb & Sons, L.L.C.$122
  • Biogen$116
  • Boston Scientific$18

What the payments were for

  • Food & beverage$1,110100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,110 in reported general payments places this provider in the 45th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$117,852
Medicare patients
443
Services billed
879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex (4 Pack)Interferon Beta-1a19$172,713
NuplazidPimavanserin Tartrate14$69,049
Glatiramer Acetate17$58,811
Aimovig AutoinjectorErenumab-Aooe40$38,995
Nurtec OdtRimegepant Sulfate27$36,074
LamictalLamotrigine16$22,967
GlatopaGlatiramer Acetate13$18,925
UbrelvyUbrogepant11$13,529
Rasagiline Mesylate37$11,205
Memantine Hcl226$7,430
Rivastigmine12$4,937
Levetiracetam113$3,817
Gabapentin198$3,602
Leucovorin Calcium21$3,371
Memantine Hcl ErMemantine Hcl13$3,190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$116$172,71319 claims
AbbVieUbrelvy$578$13,52911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,623 neurology providers in New York.

Other neurology in Huntington

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →